21
Participants
Start Date
July 3, 2019
Primary Completion Date
August 12, 2022
Study Completion Date
August 12, 2022
NeoTCR-P1 adoptive cell therapy
The investigational agent in this protocol is NeoTCR P1, an autologous adoptive T cell therapy (ACT) for patients with solid cancer. NeoTCR P1 is composed of apheresis derived CD8 and CD4 T cells that are precision genome engineered to express one autologous TCR of native sequence that targets a neoepitope (neoE) presented by human leukocyte antigen (HLA) receptors exclusively on the surface of that patient's tumor cells and not on other cells in the body.
nivolumab
Nivolumab is a human IgG4 anti-PD-1 monoclonal antibody
IL-2
IL-2 is a biologic response modifier. It is a type of protein called a cytokine.
Memorial Sloan Kettering Cancer Center, New York
Tennessee Oncology, Nashville
Northwestern University Medical Center, Chicago
University of California, Los Angeles, Los Angeles
City of Hope, Duarte
University of California, Irvine Medical Center, Orange
University of California, San Francisco, San Francisco
University of California, Davis, Sacramento
Fred Hutchinson Cancer Research Center, Seattle
Lead Sponsor
PACT Pharma, Inc.
INDUSTRY